Raymond James raised the firm’s price target on Intercept to $31 from $28 and keeps an Outperform rating on the shares. Intercept reported $68.0M Ocaliva net sales and provided an update on NASH commercial launch strategy, the analyst tells investors in a research note.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ICPT:
- Intercept reports cash balance of $435.2M as of March 31
- Intercept reports Q1 EPS (77c), consensus (65c)
- Intercept Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Update on Commercial Launch Strategy for NASH
- Intercept Announces New Data to be Presented at The European Association for the Study of the Liver (EASL) Congress 2023 and Provides Update on OCA-bezafibrate Fixed-Dose Combination (FDC) Development Program
- Is ICPT a Buy, Before Earnings?
